CAR T-Cell Therapy in Relapsed and Refractory Cancers
Relapsed and refractory cancers present a significant therapeutic challenge. These diseases persist or return despite multiple lines of standard treatment. CAR T-cell therapy has emerged as a powerful option for patients facing limited alternatives.
Resistance to chemotherapy and radiation often arises due to genetic mutations or immune evasion mechanisms within cancer cells. CAR T-cell therapy bypasses many of these mechanisms by directly targeting cancer-specific antigens through engineered immune cells.
Patients with relapsed or refractory disease undergo comprehensive evaluation to determine suitability for CAR T-cell therapy. Factors such as disease burden, prior therapies, and overall health are carefully considered.
Clinical outcomes have demonstrated that CAR T-cell therapy can induce deep and lasting remissions even in heavily pretreated patients. The therapy’s ability to expand and persist in the body contributes to sustained disease control.
Despite its promise, treatment requires close monitoring due to higher risk of side effects in patients with advanced disease. Multidisciplinary care ensures optimal balance between safety and efficacy.
CAR T-cell therapy has redefined expectations for patients with relapsed and refractory cancers, offering meaningful remission where few options previously existed.